Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Mounjaro can lead to mood changes in some users by altering gut-brain hormones, causing nutrition and hydration imbalances, blood sugar swings, and rapid weight loss that may mimic depression. Deciding whether to stay on Mounjaro or switch therapies requires careful symptom tracking, dosing adjustments, and collaboration with your healthcare provider on supportive measures.
There are many factors to consider so see below for a detailed breakdown of symptoms, risk factors, alternative medications, and step by step guidance that could impact your next steps.
Mounjaro (tirzepatide) is a novel medication approved for type 2 diabetes and widely prescribed off-label for weight management. As with any drug that affects metabolism, appetite, and gut hormones, some patients report experiencing mood changes—including feelings of depression. Understanding why this happens, how common it is, and what steps to take can help you make informed decisions about your treatment.
While outright depression is not listed as a common side effect in major prescribing guides, several biological and lifestyle factors related to Mounjaro use may contribute to low mood:
Neurochemical Effects
Nutritional and Hydration Changes
Blood Sugar Fluctuations
Rapid Weight Loss and Body Image
Gut-Brain Axis Modulation
Keep an eye on mood and behavior changes, especially if they coincide with dose increases or severe GI side effects:
• Persistent sadness or tearfulness
• Loss of interest in usual activities
• Appetite changes unrelated to dosing schedule
• Trouble sleeping or excessive sleep
• Difficulty concentrating or making decisions
• Thoughts of self-harm or hopelessness
If you notice any of the above—especially suicidal thoughts—seek help immediately.
Deciding whether to continue Mounjaro or switch to another therapy involves weighing benefits (improved glycemic control, weight loss) against potential mental health risks. Here's a step-by-step approach:
Monitor and Document
Discuss with Your Doctor
Explore Supportive Measures
Evaluate Alternative Treatments
Mental Health Support
If switching becomes necessary, these classes of medications can be considered—always under professional guidance:
• Semaglutide (Ozempic, Wegovy)
• Liraglutide (Victoza)
• DPP-4 inhibitors (e.g., sitagliptin)
• SGLT2 inhibitors (e.g., empagliflozin)
• Basal insulin formulations
Each has its own benefit–risk profile. Your provider will tailor choices to your medical history, weight-loss goals, and mental health status.
If you're uncertain whether what you're feeling is a side effect of Mounjaro or a separate issue, try using a Medically approved LLM Symptom Checker Chat Bot to help identify potential causes and get personalized guidance before your next doctor's visit.
Always treat certain signs as emergencies:
If you experience these, call emergency services or go to the nearest emergency department.
Mounjaro has transformed diabetes care and weight management for many people. However, any report of depression or significant mood changes warrants attention. By tracking symptoms, working closely with your healthcare team, and exploring supportive strategies, you can find the safest, most effective treatment path.
If you ever feel that your mental health or physical safety is at risk, speak to a doctor right away. Your wellbeing—both body and mind—comes first.
(References)
* Li H, Wang K, Zhu C, Zhang X. Tirzepatide for type 2 diabetes and obesity: a comprehensive review of its efficacy and safety. J Clin Transl Endocrinol. 2023 Nov 28;33:100346. PMID: 38046467
* Zhang X, Li Z, Zhang X, Li H. Effect of glucagon-like peptide-1 receptor agonists on depression in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab Syndr Obes. 2022 Dec 21;15:3953-3965. PMID: 36582498
* Yang D, Luo J, Fang J, Xu X, Wu Y, Yang J, Yang T, Yang X. Glucagon-like peptide-1 receptor agonists and risk of psychiatric events: a real-world study. Diabetes Obes Metab. 2023 Jun;25(6):1709-1718. PMID: 36720498
* Han J, Shen M, Xu X, Yang J, Song D. Impact of tirzepatide on health-related quality of life and patient-reported outcomes in adults with obesity or overweight with weight-related comorbidities: a systematic review and meta-analysis. Obesity (Silver Spring). 2024 Mar;32(3):570-584. PMID: 38230752
* Zhang X, Yuan Y, Wang H, Wang Q, Zhang C, Hou C, Zhang C. Analysis of adverse events associated with tirzepatide: A real-world post-marketing safety study based on the FDA Adverse Event Reporting System (FAERS) database. Front Pharmacol. 2023 May 17;14:1162319. PMID: 37274026
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.